The US Food and Drug Administration (FDA) has approved the first and only therapy for Menkes disease. Zycubo (copper histidinate), developed by US biopharmaceutical company Sentynl Therapeutics, is a subcutaneous injectable formulation given daily to deliver elemental copper to the body. In a pooled analysis of two open label, single-arm clinical trials, early treatment with […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!